Unión Europea - eslovaco - EMA (European Medicines Agency)

acino pharma gmbh  - clopidogrel - periférne vaskulárne ochorenia - antitrombotické činidlá - klopidogrel je indikovaný u dospelých na prevenciu atherothrombotic udalosti v:pacienti, ktorí trpia infarktu myokardu (od niekoľkých dní až menej ako 35 dní), ischaemic zdvih (od 7 dní do menej ako 6 mesiacov) alebo zriadené periférneho arteriálneho ochorenia. pacienti, ktorí trpia akútneho koronárneho syndrómu:- non st segment elevation akútneho koronárneho syndrómu (nestabilná angína pectoris alebo non-q vlna, infarkt myokardu), vrátane pacientov podstupujúcich stent umiestnenie týchto perkutánnej koronárnej intervencii, v kombinácii s acetylsalicylová (asa). - st segment elevation akútnom infarkte myokardu v kombinácii s asa u medicínsky liečiť pacientov nárok na thrombolytic therapy. Ďalšie informácie nájdete v časti 5.

Unión Europea - eslovaco - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogrel hydrochlorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotické činidlá - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Eslovaquia - eslovaco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pharmaceuticals works polpharma s.a., poľsko - baklofén - 63 - myorelaxantia

Eslovaquia - eslovaco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pharmaceuticals works polpharma s.a., poľsko - baklofén - 63 - myorelaxantia

Eslovaquia - eslovaco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

dr. müller pharma s.r.o., Česká republika - diklofenak - 29 - antirheumatica, antiphlogistica, antiuratica

Eslovaquia - eslovaco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pharmagen cz s.r.o., Česká republika - abirateron - 44 - cytostatica

Eslovaquia - eslovaco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

geiser pharma s.l., Španielsko - flurbiprofén - 69 - otorhinolaryngologica

Eslovaquia - eslovaco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pharmaswiss Česká republika s.r.o., Česká republika - bortezomib - 44 - cytostatica

Eslovaquia - eslovaco - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pharmagen cz s.r.o., Česká republika - kyselina zoledrónová - 87 - varia i

Unión Europea - eslovaco - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastické činidlá - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.